Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 15.56
-0.20 (-1.27%)
Aug 24, 2026, 3:04 PM CST
Jafron Biomedical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 12,049 | 15,232 | 22,720 | 17,755 | 24,741 | 42,653 | |
Market Cap Growth | -34.40% | -32.96% | 27.96% | -28.23% | -41.99% | -21.30% |
Enterprise Value | 10,904 | 14,176 | 21,627 | 16,803 | 23,822 | 41,394 |
Last Close Price | 15.56 | 19.11 | 27.48 | 20.52 | 27.93 | 47.13 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 23.11 | 28.59 | 27.70 | 40.68 | 27.81 | 35.64 |
Forward PE | 19.09 | 19.57 | 20.91 | 20.46 | 14.20 | 31.28 |
PS Ratio | 6.31 | 7.57 | 8.49 | 9.24 | 9.93 | 15.94 |
PB Ratio | 3.48 | 4.39 | 6.81 | 5.63 | 6.89 | 12.61 |
P/TBV Ratio | 3.59 | 4.53 | 7.04 | 5.85 | 7.20 | 13.27 |
P/FCF Ratio | 28.40 | 27.76 | 27.85 | 26.52 | 60.65 | 59.91 |
P/OCF Ratio | 20.28 | 21.12 | 21.62 | 19.37 | 27.99 | 34.14 |
PEG Ratio | - | 0.38 | 0.44 | 6.82 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.71 | 7.05 | 8.08 | 8.74 | 9.56 | 15.47 |
EV/EBITDA Ratio | 13.70 | 17.17 | 19.28 | 29.30 | 23.92 | 30.15 |
EV/EBIT Ratio | 16.10 | 20.01 | 21.67 | 34.79 | 25.71 | 31.27 |
EV/FCF Ratio | 25.70 | 25.84 | 26.51 | 25.10 | 58.40 | 58.14 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.36 | 0.36 | 0.42 | 0.53 | 0.36 | 0.27 |
Debt / EBITDA Ratio | 1.55 | 1.49 | 1.23 | 2.90 | 1.28 | 0.67 |
Debt / FCF Ratio | 2.92 | 2.25 | 1.70 | 2.50 | 3.13 | 1.29 |
Net Debt / Equity Ratio | -0.33 | -0.37 | -0.28 | -0.36 | -0.36 | -0.46 |
Net Debt / EBITDA Ratio | -1.44 | -1.55 | -0.83 | -1.98 | -1.29 | -1.13 |
Net Debt / FCF Ratio | -2.70 | -2.33 | -1.14 | -1.70 | -3.14 | -2.18 |
Asset Turnover | 0.37 | 0.37 | 0.49 | 0.35 | 0.49 | 0.67 |
Inventory Turnover | 1.49 | 1.40 | 1.44 | 1.07 | 1.61 | 2.54 |
Quick Ratio | 1.86 | 5.10 | 3.10 | 3.49 | 3.91 | 7.21 |
Current Ratio | 2.11 | 5.81 | 3.63 | 3.99 | 4.59 | 7.91 |
Return on Equity (ROE) | 15.98% | 15.62% | 25.10% | 12.63% | 25.26% | 38.47% |
Return on Assets (ROA) | 8.09% | 8.21% | 11.42% | 5.51% | 11.33% | 20.61% |
Return on Invested Capital (ROIC) | 23.89% | 24.84% | 36.51% | 18.25% | 38.79% | 72.80% |
Return on Capital Employed (ROCE) | 17.50% | 14.40% | 21.60% | 10.20% | 19.70% | 29.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.36% | 3.50% | 3.61% | 2.46% | 3.60% | 2.81% |
FCF Yield | 3.52% | 3.60% | 3.59% | 3.77% | 1.65% | 1.67% |
Dividend Yield | 3.29% | 2.72% | 2.91% | 1.95% | 2.40% | 1.91% |
Payout Ratio | 81.34% | 120.79% | 41.47% | 128.71% | 82.00% | 44.37% |
Buyback Yield / Dilution | -0.95% | 1.14% | 1.57% | 0.08% | 1.12% | 0.89% |
Total Shareholder Return | 2.34% | 3.86% | 4.48% | 2.03% | 3.52% | 2.79% |